Intarcia seeks approval of drug-device combo to treat Type 2 diabetes
Boston startup Intarcia Therapeutics Inc. said Monday it has applied to the Food and Drug Administration for U.S. approval of a drug-device combination to treat Type 2 diabetes, which affects the vast majority of the more than 380 million people with diabetes worldwide.
The product is a drug-loaded mini-pump that uses the company’s proprietary Medici drug delivery system to deliver long-acting medicines — they only have to be taken once or twice a year.
Intarcia, which two years ago moved its headquarters from California to Boston’s Seaport District, has raised about $1 billion from private investors that include Fidelity Investments and the Baupost Group. It has more than 300 employees, including nearly 100 in Boston. Most of the rest work at its former headquarters and manufacturing plant in Hayward, Calif., outside San Francisco.